(Q46089932)

19 December 2017

title

Novel therapeutic targets along the Th17 pathway (English)

1 reference

19 December 2017

author

Wenjun Ouyang

1

1 reference

19 December 2017

author name string

Ellen Filvaroff

2

1 reference

19 December 2017

Yan Hu

3

1 reference

19 December 2017

Jane Grogan

4

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

19 December 2017

European Journal of Immunology

published in

1 reference

19 December 2017

volume

39

1 reference

19 December 2017

page(s)

670-675

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Th17 cell differentiation: the long and winding road

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The biological functions of T helper 17 cell effector cytokines in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Transforming growth factor-beta induces development of the T(H)17 lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-21 and TGF-beta are required for differentiation of human T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Specificity and versatility in tgf-beta signaling through Smads

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

TGF-beta: a master of all T cell trades

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Inhibition of TGFbeta signaling in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Signaling and transcription in T helper development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

TH17 cells in development: an updated view of their molecular identity and genetic programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Requirement for RORgamma in thymocyte survival and lymphoid organ development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Nuclear hormone receptors in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Regulation of inflammatory responses by IL-17F

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Cutting edge: interleukin 17 signals through a heteromeric receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Molecular characterization of the human interleukin (IL)-17 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-25 regulates Th17 function in autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Regulation of gut inflammation and th17 cell response by interleukin-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

IL-21 signaling is critical for the development of type I diabetes in the NOD mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Both Th1 and Th17 are immunopathogenic but differ in other key biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The CC chemokine CCL20 and its receptor CCR6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Essential role of CCR6 in directing activated T cells to the skin during contact hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

B cell immunobiology in disease: evolving concepts from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

CD4 T cells: fates, functions, and faults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

The central role of the Th17 lineage in regulating the inflammatory/autoimmune axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Human antitransforming growth factor beta(2) monoclonal antibody--a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Cutting Edge: IL-21 Is Not Essential for Th17 Differentiation or Experimental Autoimmune Encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

A sugar switch for anti-inflammatory antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839105

7 January 2021

Identifiers

DOI

10.1002/EJI.200839105

1 reference

19 December 2017

PubMed ID

19283720

1 reference

19 December 2017